Pages that link to "Q38239401"

The following pages link to GEPNETs update: Radionuclide therapy in neuroendocrine tumors (Q38239401):

Displaying 33 items.

• Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors (Q26783272) (← links)
• Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. (Q33438326) (← links)
• Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan (Q33687453) (← links)
• Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature (Q33737587) (← links)
• Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report (Q36241229) (← links)
• Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate (Q36484229) (← links)
• MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors (Q36588574) (← links)
• AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas (Q36659064) (← links)
• Role of tumor microenvironment in tumorigenesis (Q37738074) (← links)
• Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? (Q38378364) (← links)
• Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy. (Q38625614) (← links)
• Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease (Q38794106) (← links)
• Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. (Q38842250) (← links)
• Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. (Q38861197) (← links)
• Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. (Q40587447) (← links)
• Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors (Q40773502) (← links)
• The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors (Q41192086) (← links)
• Initial Clinical Experience with 68Ga-DOTA-NOC Prepared Using 68Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based 68Ge/68Ga Generator and Freeze-dried DOTA-NOC Kits (Q42258359) (← links)
• Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies (Q47579921) (← links)
• Radiotheranostics in Cancer Diagnosis and Management (Q47719762) (← links)
• Radionuclides in oncology clinical practice - review of the literature (Q47916271) (← links)
• The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. (Q48148957) (← links)
• Targeted Therapy for Medullary Thyroid Cancer: A Review (Q49328959) (← links)
• Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors. (Q49860792) (← links)
• Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. (Q50767864) (← links)
• Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. (Q52868783) (← links)
• PSMA Theranostics: Current Status and Future Directions. (Q55023828) (← links)
• Optimizing labelling conditions of Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy (Q59469881) (← links)
• Radiation precautions for inpatient and outpatient Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours (Q64088174) (← links)
• Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting (Q64089608) (← links)
• Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. (Q64940495) (← links)
• Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC (Q85472073) (← links)
• Energy Window and Collimator Optimization in Lutetium-177 Single-photon Emission Computed Tomography Imaging using Monte Carlo Simulation (Q92712931) (← links)